US2022049233A1PendingUtilityA1
Novel mad nucleases
Est. expiryDec 10, 2039(~13.4 yrs left)· nominal 20-yr term from priority
C12N 15/102C12N 9/22C12N 2310/20C12N 15/113C12N 2800/80C12N 15/111C12N 15/907C12N 15/902
79
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A nuclease configured to perform nucleic acid-guided nuclease editing, wherein the nuclease is selected from a nuclease system comprising SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, and SEQ ID NO. 6.
2 . The nuclease of claim 1 comprising SEQ ID NO. 2.
3 . The nuclease of claim 1 comprising SEQ ID NO. 3.
4 . The nuclease of claim 1 comprising SEQ ID NO. 4.
5 . The nuclease of claim 1 comprising SEQ ID NO. 5.
6 . The nuclease of claim 1 comprising SEQ ID NO. 6.Join the waitlist — get patent alerts
Track US2022049233A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.